Robert Tansley

Robert is Investment Director at Cambridge Innovation Capital, a venture fund actively investing in IP-rich healthcare companies in the Cambridge (UK) cluster. His portfolio of investee companies includes Congenica, Inivata, STORM Therapeutics, Morphogen-IX, Cambridge Medical Robotics and Carrick Therapeutics.

After seven years working in hospital medicine, Robert joined the pharma industry gaining broad experience in development, regulatory and commercialisation at Sanofi, MHRA and Roche. He has subsequently worked for a number of UK, European and US biotech companies including Arakis (Medical Director, sold to Sosei), Treague (Founder, CEO), Avilex Pharma (founding CEO) and KalVista (part of founding management team, listed on NASDAQ, November 2016). Robert qualified in medicine from University College London, and is a member of the Royal College of Obstetricians & Gynaecologists and the Faculty of Pharmaceutical Medicine. He holds an MBA from London Business School (distinction) and an M.Phil in Biostatistics from the University of Cambridge.